New Retina Radio by Eyetube

Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively.

And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.

What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.

In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA.
Intended for a US audience only.
Sponsored by Outlook Therapeutics
References
1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd
2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026.
3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next
4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the

personal experiences that shape their practice patterns.

Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD.

And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.